Lyell Immunopharma (LYEL) Payables (2020 - 2026)
Lyell Immunopharma (LYEL) posted Payables of $5.5 million for Q1 2026, up 89.01% sequentially from $2.9 million in Q4 2025, and up 46.67% YoY from $3.7 million in Q1 2025.
Lyell Immunopharma (LYEL) Payables (2020 - 2026) Analysis & Trends
Lyell Immunopharma has reported Payables for 7 years, with the latest figure at $5.5 million in Q1 2026.
- Quarterly Payables rose 46.67% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (up 46.67% YoY) and the FY2025 annual result came in at $2.9 million, down 46.09% from the prior year.
- Payables improved to $5.5 million in Q1 2026 per LYEL's latest filing, from $2.9 million in the prior quarter.
- Over five years, Payables peaked at $6.5 million in Q1 2022 and troughed at $2.6 million in Q3 2025.
- A 5-year average of $4.5 million and a median of $4.4 million in 2023 frame the typical range for Payables.
- The sharpest annual moves came in 2025 and 2026: Payables sank 46.09% in 2025, then soared 46.67% in 2026.
- Over 5 years, Payables stood at $3.9 million in 2022, then rose by 22.98% to $4.8 million in 2023, then grew by 11.4% to $5.4 million in 2024, then tumbled by 46.09% to $2.9 million in 2025, then surged by 89.01% to $5.5 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $5.5 million, $2.9 million, and $2.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - | 3.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.88 Mn |
| Mar 31, 2026 | 5.47 Mn |
| Dec 31, 2025 | 2.89 Mn |
| Sep 30, 2025 | 2.57 Mn |
| Jun 30, 2025 | 3.38 Mn |
| Mar 31, 2025 | 3.73 Mn |
| Dec 31, 2024 | 5.37 Mn |
| Sep 30, 2024 | 3.60 Mn |
| Jun 30, 2024 | 4.20 Mn |
| Mar 31, 2024 | 4.90 Mn |
| Dec 31, 2023 | 4.82 Mn |
| Sep 30, 2023 | 4.37 Mn |
| Jun 30, 2023 | 5.81 Mn |
| Mar 31, 2023 | 5.73 Mn |
| Dec 31, 2022 | 3.92 Mn |
| Sep 30, 2022 | 4.80 Mn |
| Jun 30, 2022 | 4.25 Mn |
| Mar 31, 2022 | 6.51 Mn |
| Dec 31, 2021 | 3.21 Mn |
| Sep 30, 2021 | 3.53 Mn |